Julie Cooke Net Worth

The estimated Net Worth of Julie Cooke is at least $9.43 Million dollars as of 1 August 2024. Ms. Cooke owns over 12,632 units of Neurocrine Biosciences stock worth over $3,745,406 and over the last 5 years she sold NBIX stock worth over $5,684,666. In addition, she makes $0 as Chief Human Resource Officer at Neurocrine Biosciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Cooke NBIX stock SEC Form 4 insiders trading

Julie has made over 26 trades of the Neurocrine Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 12,632 units of NBIX stock worth $780,910 on 1 August 2024.

The largest trade she's ever made was exercising 24,000 units of Neurocrine Biosciences stock on 22 December 2023 worth over $1,752,960. On average, Julie trades about 4,111 units every 63 days since 2019. As of 1 August 2024 she still owns at least 30,834 units of Neurocrine Biosciences stock.

You can see the complete history of Ms. Cooke stock trades at the bottom of the page.

Julie Cooke biography

Julie Cooke serves as Chief Human Resource Officer of the Company. She joined Neurocrine Biosciences from the Sanford Burnham Prebys Medical Research Institute where she served as Senior Vice President for Human Resources and was a member of the executive management team. Previously, Ms. Cooke held multiple positions at Life Technologies, including being the human resource partner to the Chief Operating Officer, Division Presidents and Global Function Leads. Prior to Life Technologies, she ran human resources and was a member of the executive management team at SGX Pharmaceuticals. Ms. Cooke began her career at PepsiCo., The Pepsi Bottling Group, and Gateway , where she held positions of increasing responsibility in human resources. She holds a Bachelor of Arts in Economics from Colorado College.

How old is Julie Cooke?

Julie Cooke is 54, she's been the Chief Human Resource Officer of Neurocrine Biosciences since 2017. There are 15 older and 6 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.

What's Julie Cooke's mailing address?

Julie's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.

Insiders trading at Neurocrine Biosciences

Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.

What does Neurocrine Biosciences do?

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders

Complete history of Ms. Cooke stock trades at Neurocrine Biosciences

Neurocrine Biosciences executives and stock owners

Neurocrine Biosciences executives and other stock owners filed with the SEC include:

• Kevin Gorman,
  Chief Executive Officer, Director
• Matthew Abernethy,
  Chief Financial Officer
• Eric Benevich,
  Chief Commercial Officer
• Eiry Roberts,
  Chief Medical Officer
• Haig Bozigian,
  Chief Development Officer
• Kyle Gano,
  Chief Business Development and Strategy Officer
• Dimitri Grigoriadis,
  Chief Research Officer
• Dr. Kevin C. Gorman Ph.D.,
  CEO & Director
• Dr. Eiry Wyn Roberts,
  Chief Medical Officer
• Leslie Norwalk,
  Independent Director
• Matthew C. Abernethy,
  Chief Financial Officer
• Eric S. Benevich,
  Chief Commercial Officer
• Kyle W. Gano,
  Chief Bus. Devel. and Strategy Officer
• William Rastetter,
  Independent Chairman of the Board
• Stephen Sherwin,
  Independent Director
• Richard Pops,
  Independent Director
• George Morrow,
  Independent Director
• Gary Lyons,
  Independent Director
• Todd Tushla,
  Investor Relations
• Julie Cooke,
  Chief Human Resource Officer
• Shalini Sharp,
  Independent Director
• Darin Lippoldt,
  Chief Legal Officer and Corporate Secretary
• Malcolm Lloyd-Smith,
  Chief Regulatory Officer
• David Boyer,
  Chief Corporate Affairs Officer
• Julie S. Cooke,
  Chief HR Officer
• Darin M. Lippoldt,
  Chief Legal Officer & Corp. Sec.
• Jane Sorensen,
  Head of Investor Relations
• Dr. Jude Onyia Ph.D.,
  Chief Scientific Officer
• Dr. Dimitri E. Grigoriadis,
  Chief Research Officer
• Matt Abernethy,
  Chief Financial Officer
• Corinne H Nevinny,
  Director
• Christopher Flint O Brien,
  Sr. VP & Chief Medical Officer
• Joseph A Mollica,
  Director
• David Alexandre C Gros,
  President & COO
• Alfred Sandrock,
  Director
• Christine A Poon,
  Director
• Wylie W Vale,
  Director
• Timothy Coughlin,
  VP and Chief Financial Officer
• Jensen Margaret E Valeur,
  Senior VP and General Counsel
• Partners L P/Ilbiotechnolog...,
  
• Johanna Mercier,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Henry Pan,
  Executive VP and CMO
• Wendall Wierenga,
  EVP, Research & Development
• Richard J Ranieri,
  Sr. VP, Human Resources
• Thomas Mitchell W,
  Director
• Ingrid Delaet,
  Chief Regulatory Officer
• Paul W Hawran,
  Executive VP and CFO
• Paul J Conlon,
  Vice President Research (Biol)
• Lawrence Steinman,
  Director
• John Saunders,
  Vice President Research (Chem)
• Robert J Little,
  SVP, Commercial Operations
• D Bruce Campbell,
  Senior Vice President
• Jude Onyia,
  Chief Scientific Officer